Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-08
2007-05-08
Andres, Janet L. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S145100, C424S134100, C424S085100, C424S001410, C424S001490, C435S335000
Reexamination Certificate
active
11016047
ABSTRACT:
The present invention provides specific methods of using and administering etanercept to improve cognitive function in a human, for both the treatment and prevention of cognitive impairment, or, alternatively, to enhance cognitive function including Alzheimer's Disease, Idiopathic Dementia, and Traumatic Brain Injury. The methods of the present invention include the perispinal administration of etanercept. For the purposes of this patent “perispinal” is to be considered as referring to “perispinal extrathecal;” therefore direct intrathecal administration is excluded. Perispinal administration leads to enhanced delivery of etanercept to the brain in a therapeutically effective amount, via the vertebral venous system and/or the cerebrospinal fluid. Delivery of etanercept to the brain utilizing the methods of the present invention includes the use of the vertebral venous system to deliver etanercept to the brain via retrograde venous flow. Physical maneuvers are used to enhance delivery of etanercept to the brain via this route.
REFERENCES:
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5574022 (1996-11-01), Roberts et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5650396 (1997-07-01), Carlino et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5756482 (1998-05-01), Roberts et al.
patent: 5863769 (1999-01-01), Young
patent: 6013253 (2000-01-01), Martin et al.
patent: 6015557 (2000-01-01), Tobinick et al.
patent: 6096728 (2000-08-01), Collins et al.
patent: 6159460 (2000-12-01), Thompson et al.
patent: 6277969 (2001-08-01), Le et al.
patent: 6635250 (2003-10-01), Olmarker et al.
patent: 6649589 (2003-11-01), Olmarker et al.
patent: 2003/0148955 (2003-08-01), Pluenneke
Tobinick et al., Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly. 2003, 133: 170-177.
Hetherington et al., Potential for patient harm from intrathetical administration of preserved solutions. Med. J. Aust. 2000, 173: 141-143.
Valdueza et al., Postural dependency of the cerebral venous outflow. The Lancet 2000, 355:200-201.
Perry et al. Neurobiol Aging 2001. 22: 873-883.
Block et al. Prog. Neurobiol. 2005. 76: 77-98.
Tuppo et al. Int. J. Biochem. Cell Biol. 2005. 37: 289-305.
Tanzi et al. Neuron 2004. 43: 605-608.
Gonzales-Scarano et al. Nat. Rev Immunol. 2005. 5: 69-81.
Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. Sep. 2003;74(9):1200-5.
Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull. Aug. 15, 2003;61(3):255-60. Review.
Tobinick E.L. Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther. Aug. 2003;25(8):2279-88.
Tobinick E.L. Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clin Ther. Apr 2003;25(4):1211-8.
Tobinick E.L., Britschgi-Davoodifar S. Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly. Mar. 22, 2003;133(11-12):170-7.
Tobinick E, Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin, Jul. 2004; 20(7): 1075-1085.
Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis Sep. 2004;63:1120-1123.
Tariot PN, Federoff HJ. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord. Jul.-Sep. 2003;17 Suppl 4:S105-13.
Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis. Oct. 2003;14(1):133-45.
Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res. Oct. 1, 2003;74(1):142-7.
Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-[alpha] prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine Apr. 15, 2001;26(8):863-869.
Brisby M, Olmarker K, Larsson K, Nutu M, Rydevic B. Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur Spin J Jul. 10, 2001:DOI 10.1007/s005860100306.
Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst. 2001; 6(2):67-72.
Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry. Aug. 1994;151(8):1105-13. Review.
Aisen PS, Davis KL. The search for disease-modifying treatment for Alzheimer's disease. Neurology. May 1997;48(5 Suppl 6):S35-41. Review.
Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. Feb. 8, 2000;54(3):588-93.
Anthony JC, Breitner JC, Zandi PP, Meyer MR, Jurasova I, Norton MC, Stone SV. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology. Jun. 13, 2000;54(11):2066-71.
Breitner JC. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med. 1996;47:401-11. Review.
McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. Aug. 1996;47(2):425-32.
Edsbagge M, Tisell M, Jacobsson L, Wikkelso C. Spinal CSF absorption in healthy individuals. Am J Physiol Regul Integr Comp Physiol 287:R1450-1455, 2004.
Gisolf J, van Lieshout J, van Heusden K, et. al. Human cerebral venous outflow pathway depends on posture and central venous pressure. J Physiol 560.1:317-327(2004).
Ruiz D, Gailloud P, Rufenacht D, et. al. The craniocervical venous system in relation to cerebral venous drainage. Am J Neuroradiol 23:1500-1508, Oct. 2002.
Ibukuro K, Fukuda H, Mori K, Inoue Y. Topographic anatomy of the vertebral venous system in the thoracic inlet. Am J Radiology 176:1059-1065, Apr. 2001.
Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg 1940:112:138-149.
Batson OV. The vertebral vein system. AJ Radiology 1957 78:195-212.
Anderson R. Diodrast studies of the vertebral and cranial venous systems. J Neurosurg 1951:8:411-422.
Groen R, du Toit D, Phillips F, et. al. Anatomical and Pathological Considerations in Percutaneous Vertebroplasty and Kyphoplasty: A reappraisal of the vertebral venous system. Spine 29(13): 1465-1471 (2004).
Byrod G, Rydevik B, Johansson BR, Olmarker K. Transport of epidurally applied horseradish peroxidase to the endoneurial space of dorsal root ganglia: a light and electron microscopic study. J Peripher Nerv Syst. Dec. 2000:5(4);218-26.
Byrod G, Olmarker K, Konno S, Larsson K, Takahashi K, Rydevik B. A rapid transport route between the epidural space and the intraneural capillaries of the nerve roots. Spine. Jan. 15, 1995;20(2):138-43.
Olmarker K, Larsson K. Tumor necrosis factor alpha and nucleus-pulposus-induced nerve root injury. Spine. Dec. 1, 1998;23(23):2538-44.
Lirk P, Moriggl B, Colvin J, Keller C, Kirchmair L, Rieder J, Kolbitsch C. The incidence of lumbar ligamentum flavum midline gaps. Anesth Analg. Apr. 2004;98(4):1178-80.
Lirk P, Kolbitsch C, Putz G, Colvin J, Colvin HP, Lorenz I, Keller C, Kirchmair L, Rieder J, Moriggl B. Cervical and high thoracic ligamentum flavum frequently fails to fuse in the midline. Anesthesiology. Dec. 2003;99(6):1387-90.
Apkarian Av, Sosa Y, Sonty S, et. al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci (2004): 24(46):10410-10415.
Rutgeert
Andres Janet L.
Sutton, Esq. Ezra
Tact IP, LLC
Wang Chang-Yu
LandOfFree
Method of delivering a TNF antagonist to the brain of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of delivering a TNF antagonist to the brain of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of delivering a TNF antagonist to the brain of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3736731